[Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Recent large-scale clinical trials have provided credible evidence that angiotensin-converting enzyme inhibitors and beta-blockers can prolong the survival in patients with chronic heart failure. Treatment of asymptomatic left ventricular dysfunction is as important as treatment of symptomatic disease. Addition of aldosterone antagonists to angiotensin-converting enzyme inhibitors and beta-blockers may afford further benefits in patients with severe heart failure. If angiotensin-converting enzyme inhibitors or beta-blockers are not tolerated, angiotensin receptor blockers should be considered as the alternative. The present article will review recent advances in treatment of heart failure based on large-scale clinical trials.
Kubota
Toru
T
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences.
Takeshita
Akira
A
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D013777:Tetrazoles / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine; D019808:Losartan